Premium
A new gadolinium‐based contrast agent for magnetic resonance imaging of brain tumors: Kinetic study on a C6 rat glioma model
Author(s) -
Fonchy Emmanuel,
Lahrech Hana,
FrançoisJoubert Anne,
Dupeyre Roger,
Benderbous Soraya,
Corot Claire,
Farion Régine,
Rubin Christophe,
Décorps Michel,
Rémy Chantal
Publication year - 2001
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1158
Subject(s) - gadolinium , magnetic resonance imaging , glioma , dota , extravasation , mri contrast agent , nuclear medicine , contrast (vision) , nuclear magnetic resonance , chemistry , medicine , pathology , radiology , chelation , cancer research , physics , optics , organic chemistry
T 1 ‐weighted magnetic resonance imaging (MRI) was used to evaluate the potential interest of a new Gd‐based contrast agent, termed P760, to characterize brain tumor heterogeneity and vascularization and to delineate regions containing permeable vessels. The C6 rat glioma model was used as a model of high‐grade glioblastoma. The signal enhancement was measured as a function of time in the vascular compartment and in different regions of interest (ROIs) within the tumor after the injection of 0.02 mmol kg −1 of P760. The results were compared to those obtained after the injection of 0.1 mmol kg −1 of Gd‐DOTA. We showed that P760, in spite of a Gd concentration five times smaller, produces an enhancement in the blood pool similar to that produced by Gd‐DOTA. It was shown that P760 makes possible an excellent delineation of regions containing vessels with a damaged blood‐brain barrier (BBB). Images acquired 5–10 minutes after P760 injection showed the location of permeable vessels more accurately than Gd‐DOTA‐enhanced images. The enhancement produced in the tumor by P760 was, however, less than that produced by Gd‐DOTA. The extravasation and/or diffusion rate of P760 in the interstitial medium were found to be strongly reduced, compared to those found with Gd‐DOTA. This study suggests that the new contrast agent has promising capabilities in clinical imaging of brain tumors. J. Magn. Reson. Imaging 2001;14:97–105. © 2001 Wiley‐Liss, Inc.